ß-Catenin Stabilization Protects Against Alveolar Hemorrhage Through Amphiregulin and BATF-Mediated Regulatory T Cells

Alveolar hemorrhage (AH) is a life-threatening condition with a high mortality rate, of immune cells in its pathogenesis remains poorly defined. Here, we report of ß-catenin stabilization under Lck promoter and its impact on yet the role the protective function AH. Using a novel transgenic mouse model (CAT-Tg) with stabilized ß-catenin, we demonstrate that ß-catenin stabilization induces a distinct T-cell phenotype characterized by an expansion of central effector memory cells (CD44?, CD122?, Eomes?, T-bet?). Mechanistically, this effect was associated with suppression of key proinflammatory pathways, including reduced phosphorylation of STAT1, STAT3, and JAK1. AH was induced using pristane, and CAT-Tg mice were significantly protected from lung damage, showing reduced proteinuria and decreased pulmonary proinflammatory cytokine production compared with wild-type (WT). This protection correlated with a marked increase in FOXP3? regulatory T cells (Tregs) in CAT-Tg mice. We further identified a novel mechanism in which ß-catenin stabilization enhances lung expression of Amphiregulin and BATF, two molecules essential for Treg function and tissue repair. Adoptive transfer of Tregs from CAT-Tg mice into WT mice with pristane-induced AH conferred superior protection, as evidenced by reduced lung inflammation and proteinuria. The systemic administration of a ß-catenin agonist to mice with AH significantly attenuated disease severity. Our bioinformatic analysis confirmed that ß-catenin stabilization upregulates pathways associated with tissue repair and immune homeostasis, including PI3K-Akt, angiogenesis, and STAT5 signaling. Collectively, these findings reveal that ß-catenin stabilization protects against alveolar hemorrhage by inducing a specialized T-cell phenotype and establishing a protective Amphiregulin–BATF–Treg axis. This study identifies a novel immunomodulatory pathway with therapeutic potential for AH and other inflammatory lung diseases. Overall design: Overall design: CAT-Tg, wildtype -and vehcile versus agonist-treated WT mice following pristane challenge.